Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Core Points - Theriva Biologics has entered into a warrant inducement agreement with existing institutional investors for the immediate exercise of existing warrants to purchase up to 7,360,460 shares of common stock at a reduced exercise price of $0.54 per share, generating approximately $4.0 million in gross cash proceeds [1][2] - In exchange for the immediate exercise of existing warrants, investors will receive new unregistered warrants to purchase up to 14,720,920 shares of common stock, also at an exercise price of $0.54 per share, which will be exercisable upon stockholder approval [2][4] - The closing of the warrant inducement transaction is expected to occur on or about October 17, 2025, subject to customary closing conditions [2][3] Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [6] - The company's lead clinical-stage candidates include VCN-01, an oncolytic adenovirus targeting tumor cells; SYN-004, designed to protect the gastrointestinal microbiome during antibiotic treatment; and SYN-020, an oral formulation of intestinal alkaline phosphatase for local and systemic diseases [6]